SCHEMBL4756680

SCHEMBL4756680

CC(C)(Sc1ccccc1)C(=O)N1CCC2(CC1)Cc1ccccc1C2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.43
HSD11B1 P28845 1/20 0.42
USP2 O75604 3/20 0.39
CYP2C19 P33261 6/20 0.38
ALDH1A1 P00352 4/20 0.38
MAPK1 P28482 4/20 0.38
CYP3A4 P08684 5/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
CYP2D6 P10635 2/20 0.36
CYP2C9 P11712 2/20 0.36
FASN P49327 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HSD17B10 Q99714 3/20 0.36
CYP1A2 P05177 2/20 0.36
HPGD P15428 1/20 0.36
ALOX12 P18054 1/20 0.36
RIPK1 Q13546 1/20 0.35
HIF1A Q16665 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4705507 0.76 RIPK1 (0.56) HRH3CYP2C19ALDH1A1MAPK1CYP3A4
SCHEMBL4759099 0.75 ALDH1A1 (0.47) HRH3HSD11B1ALDH1A1MAPK1MEN1
SCHEMBL29550671 0.75 HRH3 (0.50) HRH3HSD11B1USP2CYP2C19ALDH1A1
SCHEMBL8316507 0.75 HRH3 (0.50) HRH3HSD11B1USP2CYP2C19ALDH1A1
SCHEMBL3688281 0.73 HRH3 (0.42) HRH3HSD11B1USP2CYP2C19ALDH1A1
SCHEMBL4759002 0.73 HSD11B1 (0.53) HRH3HSD11B1CYP2C19ALDH1A1MAPK1
SCHEMBL23902054 0.72 MAPK1 (0.51) HRH3CYP2C19MAPK1CYP3A4MEN1
SCHEMBL29609790 0.72 MAPK1 (0.51) HRH3CYP2C19MAPK1CYP3A4MEN1
SCHEMBL1691277 0.70 HRH3 (0.49) HRH3HSD11B1USP2CYP2C19ALDH1A1
SCHEMBL4757502 0.69 HSD11B1 (0.52) HRH3HSD11B1CYP2D6SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060009471-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-01-12 US claimed
EP-1758582-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2008-01-09 EP disclosed
EP-1758582-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-03-07 EP disclosed
US-20060009471-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-01-12 US disclosed
WO-2006002349-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009471-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 HRH3 1465/4885HSD11B1 1/4885USP2 4557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.